SCHEMBL206307

SCHEMBL206307

CN(C)C1(c2ccccc2)CCC(NC(=O)CCC(=O)N2CCC(O)(c3cccc(C(F)(F)F)c3)CC2)CC1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 11/20 0.52
OPRL1 P41146 11/20 0.52
CHRM4 P08173 1/20 0.50
CCR2 P41597 3/20 0.46
KCNH2 Q12809 2/20 0.45
OPRK1 P41145 3/20 0.44
OPRD1 P41143 2/20 0.44
SIGMAR1 Q99720 3/20 0.43
ABCB11 O95342 1/20 0.42
TP53 P04637 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
PKM P14618 1/20 0.42
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
THPO P40225 1/20 0.42
MTOR P42345 1/20 0.42
EBP Q15125 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5157641 0.90 OPRM1 (0.43) OPRM1OPRL1CHRM4CCR2KCNH2
SCHEMBL208749 0.90 CCR2 (0.45) OPRM1OPRL1CHRM4CCR2KCNH2
SCHEMBL4084332 0.81 OPRM1 (0.43) OPRM1OPRL1CCR2KCNH2
SCHEMBL5158003 0.80 CHRM4 (0.42) OPRM1OPRL1CHRM4CCR2KCNH2
SCHEMBL207055 0.78 OPRM1 (0.57) OPRM1OPRL1CCR2KCNH2SIGMAR1
SCHEMBL206135 0.77 OPRM1 (0.62) OPRM1OPRL1
SCHEMBL207753 0.75 OPRM1 (0.53) OPRM1OPRL1SIGMAR1
SCHEMBL3139132 0.72 OPRL1 (0.61) OPRM1OPRL1CHRM4OPRK1OPRD1
SCHEMBL2925749 0.72 OPRM1 (0.63) OPRM1OPRL1CHRM4OPRK1OPRD1
SCHEMBL4812413 0.71 OPRL1 (0.50) OPRM1OPRL1CHRM4OPRK1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US claimed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP claimed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US disclosed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP disclosed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed
EP-1745010-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2007-01-24 EP disclosed
WO-2005110974-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds PKD1, DDC, DPYD OPRM1 3175/4885OPRL1 2751/4885CHRM4 3939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.